Actively Recruiting
Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD
Led by University of Patras · Updated on 2026-03-24
35
Participants Needed
1
Research Sites
91 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with ssc-ild receiving double immunosuppression with or without anti fibrotic tratment
CONDITIONS
Official Title
Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of scleroderma-associated interstitial lung disease (SSc-ILD) with pulmonary fibrosis confirmed by chest HRCT
- Receiving dual immunosuppressive therapy with mycophenolate mofetil (MMF) and rituximab (RTX)
You will not qualify if you...
- Scleroderma patients without interstitial lung disease (ILD)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of patras
Pátrai, Greece
Actively Recruiting
Research Team
S
Stamatis Nick Liossis C Professor, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here